Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Filing

Personalis Prices Initial Public Offering of Common Stock


Personalis, Inc., a leader in advanced genomics for cancer, today announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Personalis. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock from Personalis at the public offering price less underwriting discounts and commissions. The company's shares are expected to begin trading on The Nasdaq Global Market on Thursday, June 20, 2019 under the trading symbol "PSNL." The offering is expected to close on June 24, 2019, subject to the satisfaction of customary closing conditions.

Morgan Stanley, BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. is acting as co-manager for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on June 19, 2019. A copy of the final prospectus relating to this offering may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; BofA Securities, Inc., Attention: Prospectus Department, NC1?004?03?43, 200 North College Street, 3rd floor, Charlotte, NC 28255?0001, or by emailing dg.prospectus_requests@baml.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631?274?2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXTtm Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).


These press releases may also interest you

at 16:47
The members of the Board of Directors of the Association des chirurgiens dentistes du Québec (ACDQ) proceeded on November 29 to elect Dr. Carl Tremblay to the office of President of the ACDQ. Accordingly, he succeeds Dr. Serge Langlois, who has held...

at 16:47
Hyundai Hope On Wheels, the non-profit for Hyundai Motor America, launches a national search to select pediatric cancer survivors for its 2020/ 2021 campaign term. Hyundai Hope On Wheels is a 501c3 non-profit organization whose goals are to fund...

at 16:45
The "Global Biosimilars Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering. The Global Biosimilars Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the...

at 16:35
FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene...

at 16:34
In the news release, Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors, issued 05-Dec-2019 by Johnson & Johnson over PR Newswire, we are advised by...

at 16:20
Enzo Biochem, Inc. , an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical...



News published on 19 june 2019 at 21:15 and distributed by: